{"id":28724,"date":"2012-03-31T07:49:10","date_gmt":"2012-03-31T11:49:10","guid":{"rendered":"http:\/\/countingpips.com\/fx\/?p=28724"},"modified":"2012-03-31T07:49:10","modified_gmt":"2012-03-31T11:49:10","slug":"immunogen-shares-rise-after-trial-announcement","status":"publish","type":"post","link":"https:\/\/www.investmacro.com\/fx\/2012\/03\/31\/immunogen-shares-rise-after-trial-announcement\/","title":{"rendered":"ImmunoGen Shares Rise After Trial Announcement"},"content":{"rendered":"<p><div id=\"grabDiv1767162\"><object id=\"GrabPlayer1767162\" width=\"542\" height=\"304\" type=\"application\/x-shockwave-flash\" align=\"middle\" data=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v486fc3c3c202f72bd3e213cafafdcd80c845c81a&#038;tgt=grabnetworks\"><param name=\"quality\" value=\"high\"\/><param name=\"allowScriptAccess\" value=\"always\"\/><param name=\"allowFullScreen\" value=\"true\"\/><param name=\"menu\" value=\"false\"\/><param name=\"wmode\" value=\"transparent\"\/><param name=\"movie\" value=\"http:\/\/player.grabnetworks.com\/swf\/GrabOSMFPlayer.swf?id=1767162&#038;content=v486fc3c3c202f72bd3e213cafafdcd80c845c81a&#038;tgt=grabnetworks\"\/><\/object><\/p>\n<div id=\"overlay-adzone\" style=\"overflow:hidden; position:relative\"><\/div>\n<\/div>\n<p>Shares of ImmunoGen (NASDAQ:IMGN) rose 10% on Friday morning after the company announced a trial of its breast-cancer treatment yielding hopeful results.Immunogen (NASDAQ:IMGN) has potential upside of 11.8% based on a current price of $15.21 and an average consensus analyst price target of $17.Immunogen is currently above its 50-day moving average (MA) of $13.68 and above its 200-day of $12.43.<\/p>\n<p><img src='http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/03\/31\/1_b4o7hyz6_thumb.jpg' \/><\/p>\n<p><!--post_img[http:\/\/cache.thenewsroom.com\/financial_news_network\/2012\/03\/31\/1_b4o7hyz6_preview.jpg]--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of ImmunoGen (NASDAQ:IMGN) rose 10% on Friday morning after the company announced a trial of its breast-cancer treatment yielding hopeful results.Immunogen (NASDAQ:IMGN) has potential upside of 11.8% based on a current price of $15.21 and an average consensus analyst price target of $17.Immunogen is currently above its 50-day moving average (MA) of $13.68 and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.investmacro.com\/fx\/2012\/03\/31\/immunogen-shares-rise-after-trial-announcement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ImmunoGen Shares Rise After Trial Announcement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-28724","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/28724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/comments?post=28724"}],"version-history":[{"count":0,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/posts\/28724\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/media?parent=28724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/categories?post=28724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.investmacro.com\/fx\/wp-json\/wp\/v2\/tags?post=28724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}